Serinus Biosciences is designing rational drug combinations for long-term cures. Our technology designs resistance-overriding therapeutics and identifies the patients who will benefit from them the most. We harmonize the breadth of systems biology with the power of AI by embedding decades of cancer research into our inference engine. Founded by MIT PhDs and supported by Y-Combinator, Serinus is eliminating the guesswork from the drug development equation.